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Abstract
Purpose Ridaforolimus is a non-prodrug mTOR inhibitor.
The safety, pharmacokinetics (PK), and antitumor activity
of oral ridaforolimus were assessed in Japanese patients
with refractory solid tumors.
Methods Ridaforolimus (20 or 40 mg) was administered
as a single dose on Day 1, followed by once daily dosing
Wve times a week for a 3-week cycle beginning on Day 8.
Full PK sampling was performed on Days 1 and 26.
Results Thirteen patients (7 at 20 mg and 6 at 40 mg)
were enrolled. The median treatment duration was 82 days.
The most common drug-related adverse events were stoma-
titis, hypertriglyceridemia, and proteinuria. Two patients
had dose-limiting toxicities (grade 3 stomatitis at 20 mg,
and grade 3 anorexia and vomiting at 40 mg). Four patients
had grade 1 interstitial pneumonitis. Ridaforolimus in the
whole blood was rapidly absorbed and slowly eliminated
with a half-life of approximately 56–58 h after a single
dose. Two patients (with non-small cell lung cancer and
angiosarcoma, respectively) achieved a partial response,
and Wve patients (one with thymic cancer and four with soft
tissue sarcomas) had a stable disease for ¸16 weeks.
Conclusions Ridaforolimus was well tolerated up to a
dose of 40 mg in Japanese patients. Preliminary evidence of
antitumor activity was observed for patients with solid
tumors. Further investigation at this dose is warranted.
Keywords Interstitial pneumonitis · mTOR inhibitor · 
Ridaforolimus · Stomatitis · Phase I study
Introduction
The mammalian target of rapamycin (mTOR) pathway
plays a central role in the proliferation and apoptosis of
cancer cells and regulates proteins critical for cell growth
and division [1–3]. The phosphatidylinositol-3-kinase (PI3K)
and mTOR pathways are often constitutively activated in
various cancer cell types, and the mTOR pathway is a
promising antitumor target. Rapamycin is the Wrst speciWc
mTOR inhibitor, and several mTOR analogs could be
candidate antitumor agents [4–6].
Ridaforolimus (formerly deforolimus, AP23573, or
MK-8669) is a novel non-prodrug rapamycin analog that is
manufactured using rapamycin as a substrate [7]. In various
in vitro studies, ridaforolimus inhibited mTOR activity and
exhibited antiproliferative activity against a broad range of
human tumor cell lines [8]. This in vitro antiproliferative
activity of ridaforolimus was additive or synergistic with
other cytotoxic and molecular-targeting anticancer agents,
such as cisplatin, docetaxel, doxorubicin, imatinib, and
trastuzumab [7]. Ridaforolimus has also shown an antitu-
mor activity in murine tumor xenograft models using
human tumor cell lines (glioblastoma, prostate cancer,
breast cancer, lung cancer, colon cancer, pancreatic cancer,
and various sarcomas) [9].
Ridaforolimus is currently being examined in Phase I
and II trials as both a single-agent therapy and a combi-
nation therapy for non-Japanese patients with advanced
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cancers [10–15]. To date, these trials have demonstrated
a favorable safety proWle and activity against a broad
range of malignancies, including breast cancer, endome-
trial cancer, hematologic malignancies, and sarcomas
[16]. Based on previous Phase I/IIa clinical studies eval-
uating various dosing schedules in non-Japanese
patients, a once daily dose of 40 mg, 5 days a week
(cumulative 4-week dose of 800 mg), was selected for
further drug evaluation.
The present Phase I study was conducted to evaluate the
safety, tolerability, and pharmacokinetics of oral ridaforoli-
mus at a once daily dose of up to 40 mg, 5 days a week, in
Japanese patients and to determine the recommended dose
for future studies.
Materials and methods
Patient eligibility
The main eligibility criteria were as follows: histologi-
cally (or cytologically) conWrmed metastatic or locally
advanced solid malignancies unresponsive to standard
therapy or for which adequate standard therapy does not
exist; an age of 20 years or older; an Eastern Cooperative
Oncology Group performance status of 0 or 1; and an
absolute neutrophil count ¸1,500/L, a platelet count
¸100,000/L, a hemoglobin level ¸9.0 g/dL, a serum
creatinine level ·1.5 mg/dL or a creatinine clearance
¸60 mL/min, a total bilirubin level ·2.0 mg/dL, an aspar-
tate aminotransferase (AST) level ·80 IU/L, and an ala-
nine aminotransferase (ALT) level ·100 IU/L. Pertinent
exclusion criteria included chemotherapy, radiotherapy,
or biological therapy within 4 weeks prior to enrollment;
primary or unstable central nervous system metastasis;
symptomatic ascites or pleural eVusion requiring treat-
ment; and a history or current evidence of pneumonitis or
pulmonary inWltration. All patients provided informed
consent, and the trial was conducted in accordance with
current Good Clinical Practice standards.
Study design, treatment, and evaluation
An open-label, non-randomized, single-center, phase I
study of ridaforolimus in patients with metastatic or locally
advanced solid tumors was conducted from June 2008 to
September 2009 (clinicaltrials.gov registration, NCT0069
4083). This study was conducted based on the Declaration
of Helsinki and the Guidelines for Clinical Evaluation
Methods of Anti-Cancer Drugs in Japan (Japanese Ministry
of Health, Labour, and Welfare notiWcation, dated Novem-
ber 1, 2005). This study was approved by the institutional
review board of the National Cancer Center Hospital.
The Wrst 28-day cycle was performed to evaluate dose-
limiting toxicities (DLTs). Patients received a single dose
(20 or 40 mg) of ridaforolimus on Day 1, followed by a
washout period of at least 6 days. Patients then received
once daily dosing for Wve consecutive days followed by a
2-day drug rest each week from Day 8 to Day 28 as inpa-
tients. For subsequent cycles, the patients were treated with
ridaforolimus once daily, 5 days a week, in a 21-day cycle.
Patients continued to receive the therapy unless they met
any of the discontinuation criteria, such as disease progres-
sion or unacceptable toxicity.
Dose escalation followed a conventional “3 + 3” design.
If 1 out of 3 patients developed a DLT at dose level 1
(20 mg) during the Wrst cycle, three additional patients were
treated at the same dose level, for a total of six patients. If
either 0/3 or 1/6 patients developed a DLT at dose level 1,
the study progressed to dose level 2 (40 mg). If two or more
patients developed DLTs, the dose was not escalated to
level 2. At dose level 2, a toxicity evaluation was also per-
formed for six patients.
Toxicity was graded and recorded according to the
National Cancer Institute—Common Terminology Criteria
for Adverse Events (CTCAE), version 3.0, and DLT was
deWned as any of the following events judged to be related
to the study drug (i.e., classiWed as possibly related, proba-
bly related, or deWnitely related) during the Wrst cycle (DLT
evaluation period): Grade 4 neutropenia persisting for
>5 days, Grade 3 or 4 neutropenia associated with fever
(temperature >38.5°C), Grade 4 thrombocytopenia, Grade
3 or Grade 4 non-hematologic toxicity (except for alopecia,
toxicities controllable with appropriate supportive care, and
transient electrolyte abnormalities).
Antitumor activity was investigated in an exploratory
fashion based on RECIST, version 1.0.
Pharmacokinetic assessment
The ridaforolimus concentration in the whole blood and
plasma and the pharmacokinetic parameters were evaluated
during the Wrst treatment cycle. Blood samples were col-
lected according to the following sampling schedule: pre-
dose and 0.5, 1.0, 2.0, 4.0, 8.0, 24, 72, 96, and 168 h
postdose on Day 1; predose on Days 15, 18, 22, and 23, and
predose and 0.5, 1.0, 2.0, 4.0, 8.0, and 24 h postdose on
Day 26. Ridaforolimus in the whole blood and plasma was
analyzed using high-performance liquid chromatography
with tandem mass spectrometric detection. The apparent
terminal t1/2 was estimated from the best-Wt variables to the
log-linear portion of the blood concentration–time curve
using an unweighted linear regression. The area under the
curve over the Wrst 24 h (AUC0–24 h) was calculated using
the linear up/log down trapezoidal method up to 24 h post-
dose. Tmax, Cmax, and Ctrough were obtained by inspectingCancer Chemother Pharmacol (2012) 69:1099–1105 1101
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the concentration–time data. To assess the accumulation of
ridaforolimus in the whole blood, individual whole blood
AUC0–24 h values (from subjects evaluated on both days
only) were natural log-transformed and evaluated using a
linear mixed eVects model with Wxed eVects for dose and
day (Day 1, Day 26), dose-by-day interaction, and a ran-
dom eVect for subject. The geometric means and 95% con-
Wdence intervals of the AUC0–24 h, Cmax, and Ctrough were
calculated for each dose and day using this model. The geo-
metric mean accumulation ratios (Day 26/Day 1) and the
90% conWdence intervals for these parameters were also
calculated from the model for each dose.
Results
Patient characteristics
Thirteen Japanese patients with solid tumors were enrolled
and were evaluated in this study. The baseline characteris-
tics of the patients are summarized in Table 1. The age
range was 26–68 years (median: 54 years). Seven patients
had sarcomas. The median number of prior chemotherapy
regimens was 3 (range: 0–12). One patient treated at dose
level 1 (20 mg) was excluded from the DLT evaluation
because the achieved dose intensity was <75% of the
scheduled dose; this patient developed tumor-associated
pneumonia, which was unrelated to the study drug. There-
fore, one new patient was added, making a total of seven
patients treated at dose level 1. Six patients were treated at
dose level 2 (40 mg). The median treatment duration was
35.0 days at dose level 1 and 88.5 days at dose level 2.
None of the patients treated at dose level 2 required a dose
reduction. The longest treatment duration was 234 days
achieved in one patient who was treated at dose level 2. Six
patients discontinued treatment because of adverse events,
and seven discontinued treatment because of progressive
disease.
Safety evaluation
A summary of the DLTs is given in Table 2. As noted, one
of the seven patients treated at dose level 1 (20 mg) was
excluded from the evaluation. Of the six patients who were
evaluated at dose level 1, one patient developed Grade 3
stomatitis. In addition, one of the six patients evaluated for
DLTs at dose level 2 (40 mg) developed Grade 3 anorexia
and Grade 3 vomiting. The time until the onset of the DLT
after the administration of ridaforolimus was 8 days for the
Grade 3 stomatitis and 23 days for both the Grade 3 anor-
exia and the Grade 3 vomiting. All the DLTs were manage-
able with medical treatment or the discontinuation of
ridaforolimus, and the patients recovered to ·Grade 1
within 3 to 10 days.
The common clinical and laboratory adverse events
detected in all the treatment cycles are summarized in
Table 3. The most common clinical adverse events related
to ridaforolimus treatment were stomatitis (13/13: 100%),
hypertriglyceridemia (9/13: 69.2%), skin rash (6/13: 61.5%),
hypercholesterolemia (6/13: 46.2%), and proteinuria (6/13:
46.2%). The most common hematological adverse events
were thrombocytopenia (5/13: 38.5%), leucopenia (4/13:
30.8%), and neutropenia (4/13: 30.8%).
Four patients were diagnosed as having drug-induced
interstitial pneumonitis based on independent reviews of
chest X-ray Wlms or CT scans, but none of the patients were
symptomatic (Grade 1). Three of the four patients were
managed with treatment interruption, while one patient
continued to receive treatment without dose modiWcation.
The pneumonitis resolved in all the patients by the end of
the study.
Table 1 Baseline characteristics of the subjects
Characteristic N =1 3
Age, year (range) 54 (26–68)
Male/female 6/7
Weight, kg 60.0 (37.9–97.8)
Performance status 0/1 9/4
Prior therapy
Chemotherapy 12
Number of previous regimens, median (range) 3 (0–12)
Surgery 12
Radiation 5
Tumor type
Non-small cell lung cancer 5
Osteosarcoma 2
Liposarcoma 2
Leiomyosarcoma 2
Renal angiosarcoma 1
Thymic cancer 1
Table 2 Summary of dose-limiting toxicities (DLTs) (Cycle 1)
a n/N No. of patients with DLT/No. of patients at the dose level
b One patient was excluded from the DLT evaluation
Dose 
level
Dose 
(mg)
n/Na DLTs Time to 
onset (days)
Level 1 20 1/6b Grade 3 stomatitis 8
Level 2 40 1/6 Grade 3 anorexia 23
Grade 3 vomiting1102 Cancer Chemother Pharmacol (2012) 69:1099–1105
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Pharmacokinetic evaluation
The pharmacokinetic parameters (evaluated during cycle 1) are
summarized in Table 4. Ridaforolimus exhibited a lag time of
1–4 h on Day 1 for systemic absorption, i.e., the whole blood
concentration was below the quantitation limit (<0.2 ng/mL)
for 2–4 h after the administration of 20 mg and for 1–2 h after
the administration of 40 mg. The Cmax was reached approxi-
mately 4 h after administration on Days 1 and 26, although the
median Tmax was 7.93 h on Day 1 after a dose of 20 mg. The
whole blood concentration declined in a bi-exponential man-
ner, and the apparent terminal-phase half-life (t1/2) (obtained at
up to 168 h after a single dose on Day 1) ranged from 55.8 to
58.0 h (harmonic mean). Because of this long t1/2, the value
could not be calculated on Day 26 because the blood samples
were only collected for 24 h after administration.
The mean whole blood Ctrough values tended to reach a
steady state after about 1 week of ridaforolimus administra-
tion, with moderate accumulation (i.e., an increase of less
than or approximately twofold from Day 1 to Day 26)
observed based on the AUC0–24 h, Cmax, and Ctrough values.
The plasma concentration of ridaforolimus was substan-
tially lower than the whole blood concentration, indicating
a high blood-to-plasma ratio.
EYcacy evaluation
The response to oral ridaforolimus and the duration of anti-
tumor activity are summarized in Table 5.
Two patients achieved a partial response: one patient
with non-small cell lung cancer (NSCLC) and one patient
with angiosarcoma (Fig. 1). The time until the response
was 28 days for both patients. The duration of the response
and the time-to-progression (TTP) were 212 and 240 days,
respectively, for the patient with NSCLC, who was treated
at dose level 1 (20 mg). The response duration and the TTP
were not calculated for the patient with the angiosarcoma
because this patient discontinued the treatment in response
Table 3 Common drug-related 
adverse events in all cycles 
(>30%)
20 mg (n = 7) 40 mg (n = 6) All patients (n =1 3 )
Grades 1–2 Grades 3–4 Grades 1–2 Grades 3–4 Grades 1–2 Grades 3–4
Hematologic
A n e m i a 1133 1 4
Thrombocytopenia 2 0 3 0 5 0
Neutropenia 1 2 1 0 2 2
Leukopenia 1 1 2 0 3 1
Non-hematologic
S t o m a t i t i s 71601 2 1
Hypertriglyceridemia 5 0 4 0 9 0
Proteinuria 3 0 3 0 6 0
Hypercholesterolemia 3 0 3 0 6 0
R a s h 5021 5 1
A n o r e x i a 2021 4 1
Hyperglycemia 2 0 2 1 4 1
Hypoalbuminemia 2 0 3 0 5 0
Constipation 3 0 1 0 4 0
Fatigue 1 0 3 0 4 0
Loss of body weight 0 0 4 0 4 0
Interstitial pneumonitis 1 0 3 0 4 0
Table 4 Whole blood pharmacokinetic parameters of ridaforolimus
a Geometric mean (95% conWdence interval), b Median (min, max),
c Harmonic mean (jack-knife SD), d Geometric mean ratio (90% coxn-
Wdence interval), e N =5 ,   f N =4
Parameters Day Dose level 1 
20 mg (n =7 )
Dose level 2 
40 mg (n =6 )
AUC0–24 h 
(ng h/mL)a
1 1,100 (721, 1,680) 1,470 (914, 2,360)
26 1,670 (1,090, 2,550)e 2,120 (1,320, 3,410)f
Cmax (ng/mL)a 1 113 (73.3, 175) 187 (115, 304)
26 155 (101, 240)e 188 (116, 306)f
Tmax (h)b 1 7.93 (3.90, 23.9) 4.00 (4.00, 8.00)
26 4.00 (3.98, 4.00)e 4.04 (4.00, 8.15)f
t1/2 (h)c 1 58.0 § 8.27 55.8 § 4.85
26 – –
Accumulation ratio (Day 26/Day 1)d
AUC0–24 h 1.51 (1.14, 2.01) 1.44 (1.05, 1.99)
Cmax 1.37 (0.959, 1.97) 1.01 (0.674, 1.50)
Ctrough 2.02 (1.61, 2.52) 1.76 (1.37, 2.25)Cancer Chemother Pharmacol (2012) 69:1099–1105 1103
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to an adverse event. Five patients exhibited stable disease
for longer than 16 weeks.
Discussion
The primary objective of the present study was to conWrm
the safety and tolerability of ridaforolimus in Japanese
patients with advanced solid tumors for whom standard
treatment had failed. The initial dose was set at half the
maximum tolerated dose (MTD) in previous Phase I clini-
cal studies and the optimal dose in Phase II clinical studies
in which various dosing schedules were studied in non-Jap-
anese patients [10–13]. The administration regimen for this
study was selected to enable a greater cumulative 4-week
dose. The MTD using a once daily, Wve-times-a-week regi-
men was 40 mg, and the cumulative 4-week dose was
800 mg in non-Japanese patients, whereas the MTD using a
daily regimen was 10 mg and the cumulative dose was
280 mg in non-Japanese patients. Two days of dose “rest”
facilitated a higher cumulative AUC and greater tolerability
than continuous daily dosing. In addition, the long half-life
enabled intermittent dosing. Therefore, a 40 mg dose
administered Wve times a week was selected as the recom-
mended dose and schedule.
In general, oral ridaforolimus (40 mg daily, Wve times a
week) exhibited an acceptable safety proWle in Japanese
patients with advanced solid tumors. Most of the common
symptomatic adverse events in the present study were also
reported for orally or intravenously administered ridaforolimus
Table 5 Antitumor activity of 
ridaforolimus
Patient 
number
Tumor type Dose No. of prior 
regimens
Best 
response
Duration of 
stable disease 
(weeks)
1 Osteosarcoma 20 mg 5 SD 3.7
2 NSCLC (adenocarcinoma) 3 PD –
3 Thymic cancer 4 SD 16.3
4 NSCLC (squamous cell carcinoma) 3 PR –
5 Liposarcoma 1 SD 16.1
6 NSCLC (adenocarcinoma) 5 SD 4.0
7 NSCLC (adenocarcinoma) 1 SD 4.0
8 Osteosarcoma 40 mg 6 SD 4.0
9 Liposarcoma 0 SD 17.3
10 Leiomyosarcoma 5 SD 16.3
11 Leiomyosarcoma 1 SD 17.1
12 NSCLC (adenocarcinoma) 12 PD –
13 Renal angiosarcoma 1 PR –
PR partial response, SD stable 
disease, PD progressive disease, 
NSCLC non-small cell lung 
cancer
Fig. 1 CT scans showing a partial response (in Patient 13). a Baseline, longest diameter of 42 mm; and b Day 28, longest diameter of 21 mm1104 Cancer Chemother Pharmacol (2012) 69:1099–1105
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in non-Japanese patients. Based on the above Wndings, the
overall safety proWle of ridaforolimus in Japanese patients
with advanced solid tumors in the present study was gener-
ally consistent with that observed previously in phase I/IIa
studies in non-Japanese patients with refractory or
advanced solid tumors. The PK proWles of ridaforolimus in
the Japanese patients did not diVer from the internal PK
data obtained in non-Japanese patients with advanced solid
tumors (data not shown).
One patient at dose level 1 (20 mg) experienced a DLT
(Grade 3 stomatitis), and one patient at dose level 2 (40 mg)
experienced two DLTs (Grade 3 anorexia and Grade 3
vomiting). All of the DLTs were reversible and were
promptly resolved after the completion of the study drug
administration. In the previous Phase I/IIa clinical study
performed in non-Japanese patients with refractory or
advanced solid cancer, the DLTs noted for the same dosing
schedule (40 mg daily, Wve times a week) were stomatitis
and fatigue [17].
Stomatitis was seen in all 13 patients enrolled in this
study and has been commonly reported as a drug-related
adverse event in other clinical studies examining ridaforoli-
mus. The stomatitis lesions consisted of aphthous-like
mouth sores that were distinct from chemotherapy-associ-
ated mucositis. In the present study, the median time until
the onset of stomatitis was 11 days, indicating that this tox-
icity occurs relatively soon after the start of ridaforolimus
administration. Most cases resolved after dose interruption
or discontinuation. Preventive measures such as oral care,
local analgesia, and other supportive therapies should be
considered during the administration of ridaforolimus. Sto-
matitis and mucosal inXammation have also been com-
monly reported in association with other mTOR inhibitors,
such as everolimus and temsirolimus [18–21].
The incidence of interstitial pneumonitis was higher in
the present report than in previous studies examining ridaf-
orolimus [11]. However, all the cases were mild, asymp-
tomatic, and limited to imaging changes (Grade 1), and all
the patients had recovered by the end of the study period.
These events occurred at 2–5 months after the start of treat-
ment. The Wndings were consistent with the results of a
study examining the mTOR inhibitor everolimus in Japa-
nese patients with advanced renal cell carcinoma; the inci-
dence of pneumonitis in this previous study was 27%,
which was higher than the 11% overall rate reported in
patients with renal cell carcinoma [18]. Because of the
small number of patients in each study, however, whether
this incidence was related to ethnicity remains uncertain.
The relatively high incidence might also result from more
intensive monitoring for lung injuries because of the
increased rates of interstitial pneumonitis, bronchiolitis
obliterans, and persistent organizing pneumonia that are
observed when mTOR inhibitors are used [22]. Accord-
ingly, pulmonary opacities on chest radiographs should be
carefully distinguished from progressive metastatic disease,
and pulmonary symptoms should be carefully monitored.
Notably, there were Wve patients with NSCLC in this study.
Interstitial pneumonitis occurred in one of these Wve
NSCLC patients, whereas the other three cases occurred
among eight patients with other cancer types, suggesting
that the incidence of interstitial pneumonitis did not diVer
between patients with lung cancer and non-lung cancer
patients.
Our exploratory analysis of eYcacy revealed a partial
response in two patients (NSCLC and renal angiosarcoma),
and Wve patients exhibited stable disease for longer than
16 weeks. These results suggest that ridaforolimus may be
active against advanced solid tumors, including sarcoma.
Ridaforolimus has also demonstrated clinical activity
against sarcomas and other cancers, including endometrial
cancer [23], and is currently being studied as a maintenance
treatment for soft tissue and bone sarcomas. In addition, a
Phase II study of ridaforolimus used in combination with
insulin-like growth factor-1 inhibitor (IGF-1) for breast
cancer is underway. Importantly, in a recent Phase III
sarcoma maintenance study [24], ridaforolimus met the
prespeciWed study endpoint of a statistically signiWcant
improvement in progression-free survival, compared with a
placebo group (hazard ratio = 0.72, P = 0.0001, stratiWed
log-rank).
In conclusion, the safety and tolerability of ridaforoli-
mus at a dose of up to 40 mg were conWrmed in Japanese
patients, and an exploratory eYcacy analysis supported the
usefulness of ridaforolimus for the treatment of advanced
solid tumors. Additional studies are ongoing to conWrm the
safety and eYcacy of ridaforolimus.
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